BIOMAT Database Logo BIOMAT Database Logo

[Plasma levels of insulin and leptin in patients with morbid obesity and anorexia nervosa after weight loss or gain, respectively]. 2000

L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Servicio de Endocrinología y Nutricion, Hospital Universitario Puerta del Mar, Cádiz. lescobar@nhcges.com

The present study was conducted in order to analyze the relationship existing between leptin and insulin levels in massive weight loss and weight recovery. Thirteen patients with severe obesity, 14 patients with anorexia nervosa and 13 healthy control subjects were studied. The patients with severe obesity underwent a vertical banded gastroplasty followed by an 800 kcal/day diet for 12 weeks. They were evaluated prior to (body mass index [BMI] 51.2 +/- 8.8 Kg/m2) and after drastic weight loss (BMI 40.6 +/- 6.7 Kg/m2). Patients with anorexia nervosa were treated exclusively with nutritional therapy during 12 weeks, and they were evaluated at their lowest weight status (BMI 16.2 +/- 2.2 Kg/m2) and after weight recovery (BMI 17.9 +/- 2.3 Kg/m2). The BMI of the normal subjects was in the normal range of 20 to 27 Kg/m2 (average 22.8 +/- 2.6 Kg/m2). BMI, percentage of body fat, waist circumference, and serum levels of leptin, insulin, and C-peptide were determined in each patient and normal subject. In severely obese patients, serum leptin and insulin decreased significantly after drastic weight reduction (leptin: from 51.8 +/- 22.3 to 23.7 +/- 10.2 ng/ml; insulin: from 27.1 +/- 13.3 to 17.2 +/- 7.2 mU/ml). In patients with anorexia nervosa, the mean serum leptin levels were significantly higher after weight recovery (5.5 +/- 3.2 vs 7.6 +/- 6 ng/ml). Serum leptin in the severe obesity group correlated positively with BMI, percentage body fat and waist circumference before and after weight loss. In those patients suffering from anorexia nervosa, serum leptin correlated positively with the BMI, percentage of body fat, and waist circumference in the low weight state and after weight recovery. In addition, their serum insulin correlated with BMI and waist circumference after weight recovery. These data reveal that serum leptin concentration correlates significantly with the BMI and body fat content 1) in subjects with a range of weight and caloric intake, 2) in obese patients after drastic weight loss; 3) in anorexic patients after weight gain; and that hyper- or normoinsulinemia do not seem to have any influence on the leptin changes caused by weight loss or gain.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009767 Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2. Morbid Obesity,Obesity, Severe,Morbid Obesities,Obesities, Morbid,Obesities, Severe,Severe Obesities,Severe Obesity
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006946 Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. Compensatory Hyperinsulinemia,Endogenous Hyperinsulinism,Exogenous Hyperinsulinism,Hyperinsulinemia,Hyperinsulinemia, Compensatory,Hyperinsulinism, Endogenous,Hyperinsulinism, Exogenous

Related Publications

L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa.
July 2004, Psychoneuroendocrinology,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Serum leptin and gonadotropin levels in patients with anorexia nervosa during weight gain.
January 1999, Molecular psychiatry,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
The effect of therapeutically induced weight gain on plasma leptin levels in patients with anorexia nervosa.
January 2003, Journal of psychiatric research,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Determinants of plasma adiponectin levels in patients with anorexia nervosa examined before and after weight gain.
September 2005, European journal of nutrition,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Circadian plasma leptin levels in patients with anorexia nervosa: relation to insulin and cortisol.
January 1998, Hormone research,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
PCSK9 and leptin plasma levels in anorexia nervosa.
March 2024, Hormones (Athens, Greece),
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Increased ferritin levels in patients with anorexia nervosa: impact of weight gain.
September 2016, Eating and weight disorders : EWD,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Weight gain with anorexia nervosa.
September 2000, The American journal of psychiatry,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Serum leptin, gonadotropin, and testosterone concentrations in male patients with anorexia nervosa during weight gain.
July 2001, The Journal of clinical endocrinology and metabolism,
L Escobar, and J M Freire, and J A Girón, and J M Vázquez, and M Pajares, and J Ortego, and I Gavilán, and A J Chover, and M Carrasco, and R Epinosa, and F Marín, and M Aguilar
Gonadotropin response to clomiphene and plasma leptin levels in weight recovered but amenorrhoeic patients with anorexia nervosa.
June 2004, Journal of endocrinological investigation,
Copied contents to your clipboard!